Overview

A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED)

Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
0
Participant gender:
All
Summary
This is a study to evaluate the safety and tolerability of Caelyx used for the treatment of metastatic breast cancer (MBC), focusing on infusion reaction and palmar-plantar erythrodysesthesia (PPE).
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Doxorubicin
Liposomal doxorubicin
Criteria
Inclusion Criteria:

- Patients with metastatic breast cancer

Exclusion Criteria:

- History of hypersensitivity to Caelyx or its components

- Women who are pregnant or breast-feeding

- Patients with severe myelosuppression